Clinical Trial Update: Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial is evaluating a triple combination of encorafenib, binimetinib, and cetuximab in patients with BRAF V600E-mutated/pMMR localized col…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• BRAFTOVI (ENCORAFENIB)
• ERBITUX (cetuximab)
• MEKINIST (trametinib)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Colorectal Cancer, Colon Cancer | Phase 2 | Status: COMPLETED